{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:53:13Z","timestamp":1788796393573,"version":"build-2803163510"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Functional dyspepsia (FD) is a disorder that presents with chronic dyspepsia, which is not only very common but also highly affects quality of life of the patients. In Japan, FD became a disease name for national insurance in 2013, and has been gradually recognized, though still not satisfactory. Following the revision policy of Japanese Society of Gastroenterology (JSGE), the first version of FD guideline was revised this time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Like previously, the guideline was created by the GRADE (grading of recommendations assessment, development and evaluation) system, but this time, the questions were classified to background questions (BQs, 24 already clarified issues), future research questions (FRQs, 9 issues cannot be addressed with insufficient evidence), and 7 clinical questions that are mainly associated with treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Conclusion<\/jats:title>\n                    <jats:p>These revised guidelines have two major features. The first is the new position of endoscopy in the flow of FD diagnosis. While endoscopy was required to all cases for diagnosis of FD, the revised guidelines specify the necessity of endoscopy only in cases where organic disease is suspected. The second feature is that the drug treatment options have been changed to reflect the latest evidence. The first-line treatment includes gastric acid-secretion inhibitors, acetylcholinesterase (AChE) inhibitors (acotiamide, a prokinetic agent), and Japanese herbal medicine (rikkunshito). The second-line treatment includes anxiolytics \/antidepressant, prokinetics other than acotiamide (dopamine receptor antagonists, 5-HT4 receptor agonists), and Japanese herbal medicines other than rikkunshito. The patients not responding to these treatment regimens are regarded as refractory FD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-021-01843-7","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T06:02:32Z","timestamp":1642744952000},"page":"47-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Evidence-based clinical practice guidelines for functional dyspepsia 2021"],"prefix":"10.1007","volume":"57","author":[{"given":"Hiroto","family":"Miwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Kasugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Futagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiyasu","family":"Arisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Joh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooru","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"1843_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00535-014-1022-3","volume":"50","author":"H Miwa","year":"2015","unstructured":"Miwa H, Kusano M, Arisawa T, et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2015;50:125\u201339.","journal-title":"J Gastroenterol"},{"key":"1843_CR2","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","volume":"130","author":"J Tack","year":"2006","unstructured":"Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466\u201379.","journal-title":"Gastroenterology"},{"key":"1843_CR3","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","volume":"150","author":"V Stanghellini","year":"2016","unstructured":"Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380\u201392.","journal-title":"Gastroenterology"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1440-1746.2011.07037.x","volume":"27","author":"H Miwa","year":"2012","unstructured":"Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012;27:626\u201341.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MCG.0b013e31829f2e25","volume":"48","author":"B Zhao","year":"2014","unstructured":"Zhao B, Zhao J, Cheng WF, et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol. 2014;48:241\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"1843_CR6","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;CD002096.","DOI":"10.1002\/14651858.CD002096.pub4"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1523-5378.2007.00520.x","volume":"12","author":"X Jin","year":"2007","unstructured":"Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter. 2007;12:541\u20136.","journal-title":"Helicobacter"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353\u201367.","journal-title":"Gut"},{"key":"1843_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2982.2011.01859.x","volume":"24","author":"J Matsuzaki","year":"2012","unstructured":"Matsuzaki J, Suzuki H, Asakura K, et al. Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil. 2012;24:325-e164.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2169\/internalmedicine.50.4731","volume":"50","author":"N Manabe","year":"2011","unstructured":"Manabe N, Haruma K, Kamada T, et al. Changes of upper gastrointestinal symptoms and endoscopic findings in Japan over 25\u00a0years. Intern Med. 2011;50:1357\u201363.","journal-title":"Intern Med"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"3420548","DOI":"10.1155\/2019\/3420548","volume":"2019","author":"L Du","year":"2019","unstructured":"Du L, Kim JJ, Chen B, et al. Gene polymorphisms and susceptibility to functional dyspepsia: a systematic review and meta-analysis. Gastroenterol Res Pract. 2019;2019:3420548.","journal-title":"Gastroenterol Res Pract"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00535-014-1014-3","volume":"50","author":"T Oshima","year":"2015","unstructured":"Oshima T, Fukui H, Watari J, et al. Childhood abuse history is associated with the development of dyspepsia: a population-based survey in Japan. J Gastroenterol. 2015;50:744\u201350.","journal-title":"J Gastroenterol"},{"key":"1843_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/apt.13006","volume":"41","author":"S Futagami","year":"2015","unstructured":"Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther. 2015;41:177\u201388.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000243783","volume":"81","author":"LB Olafsdottir","year":"2010","unstructured":"Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Natural history of functional dyspepsia: a 10-year population-based study. Digestion. 2010;81:53\u201361.","journal-title":"Digestion"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3109\/00365521003592663","volume":"45","author":"N Manabe","year":"2010","unstructured":"Manabe N, Haruma K, Hata J, et al. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? Scand J Gastroenterol. 2010;45:567\u201372.","journal-title":"Scand J Gastroenterol"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2169\/internalmedicine.50.5678","volume":"50","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Chiba T. Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: based on the large-scale survey, FUTURE study. Intern Med. 2011;50:2269\u201376.","journal-title":"Intern Med"},{"key":"1843_CR17","first-page":"42","volume":"20","author":"T Oshima","year":"2013","unstructured":"Oshima T, Ikeo K, Miwa H. Factors affecting the medical consultation by dyspepsia in Japan. Jpn Soc Psychosom Med Dig Dis. 2013;20:42\u20134 (in Japanese).","journal-title":"Jpn Soc Psychosom Med Dig Dis"},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.1440-1746.2010.06249.x","volume":"25","author":"M Kaji","year":"2010","unstructured":"Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25:1151\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S2468-1253(18)30003-7","volume":"3","author":"I Aziz","year":"2018","unstructured":"Aziz I, Palsson OS, Tornblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3:252\u201362.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.5056\/jnm.2014.20.1.104","volume":"20","author":"H Yamawaki","year":"2014","unstructured":"Yamawaki H, Futagami S, Shimpuku M, et al. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil. 2014;20:104\u201312.","journal-title":"J Neurogastroenterol Motil"},{"key":"1843_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5056\/jnm20117","volume":"27","author":"T Oshima","year":"2021","unstructured":"Oshima T, Siah KTH, Kim YS, et al. Knowledge, attitude, and practice survey of gastroparesis in Asia by Asian Neurogastroenterology and Motility Association. J Neurogastroenterol Motil. 2021;27:46\u201354.","journal-title":"J Neurogastroenterol Motil"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-018-0038-z","volume":"4","author":"M Camilleri","year":"2018","unstructured":"Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nat Rev Dis Prim. 2018;4:41.","journal-title":"Nat Rev Dis Prim"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.cgh.2017.04.011","volume":"15","author":"PJ Pasricha","year":"2017","unstructured":"Pasricha PJ, Camilleri M, Hasler WL, et al. White paper AGA: gastroparesis: clinical and regulatory insights for clinical trials. Clin Gastroenterol Hepatol. 2017;15:1184\u201390.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5056\/jnm16173","volume":"23","author":"H Asano","year":"2017","unstructured":"Asano H, Tomita T, Nakamura K, et al. Prevalence of gastric motility disorders in patients with functional dyspepsia. J Neurogastroenterol Motil. 2017;23:392\u20139.","journal-title":"J Neurogastroenterol Motil"},{"key":"1843_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ajg.2016.499","volume":"112","author":"H Vanheel","year":"2017","unstructured":"Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological abnormalities in functional dyspepsia subgroups according to the Rome III criteria. Am J Gastroenterol. 2017;112:132\u201340.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1023\/A:1018803129779","volume":"43","author":"AO Quartero","year":"1998","unstructured":"Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998;43:2028\u201333.","journal-title":"Dig Dis Sci"},{"key":"1843_CR27","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S0016-5085(98)70012-5","volume":"115","author":"J Tack","year":"1998","unstructured":"Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346\u201352.","journal-title":"Gastroenterology"},{"key":"1843_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1053\/gast.1996.v110.pm8612991","volume":"110","author":"V Stanghellini","year":"1996","unstructured":"Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology. 1996;110:1036\u201342.","journal-title":"Gastroenterology"},{"key":"1843_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2982.2012.01897.x","volume":"24","author":"H Kusunoki","year":"2012","unstructured":"Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24:540\u20135.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2036.2011.04918.x","volume":"35","author":"T Oshima","year":"2012","unstructured":"Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Ther. 2012;35:175\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1540\/jsmr.46.1","volume":"46","author":"M Ishii","year":"2010","unstructured":"Ishii M, Kusunoki H, Manabe N, et al. Duodenal hypersensitivity to acid in patients with functional dyspepsia-pathogenesis and evaluation. J Smooth Muscle Res. 2010;46:1\u20138.","journal-title":"J Smooth Muscle Res"},{"key":"1843_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00535-012-0602-3","volume":"48","author":"T Arisawa","year":"2013","unstructured":"Arisawa T, Tahara T, Shiroeda H, et al. Genetic polymorphisms of SCN10A are associated with functional dyspepsia in Japanese subjects. J Gastroenterol. 2013;48:73\u201380.","journal-title":"J Gastroenterol"},{"key":"1843_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.gastro.2005.04.012","volume":"129","author":"F Mearin","year":"2005","unstructured":"Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98\u2013104.","journal-title":"Gastroenterology"},{"key":"1843_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00535-019-01550-4","volume":"54","author":"H Miwa","year":"2019","unstructured":"Miwa H, Oshima T, Tomita T, et al. Recent understanding of the pathophysiology of functional dyspepsia: role of the duodenum as the pathogenic center. J Gastroenterol. 2019;54:305\u201311.","journal-title":"J Gastroenterol"},{"key":"1843_CR35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/ajg.2010.151","volume":"105","author":"S Futagami","year":"2010","unstructured":"Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-\/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010;105:1835\u201342.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/gutjnl-2012-303857","volume":"63","author":"H Vanheel","year":"2014","unstructured":"Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63:262\u201371.","journal-title":"Gut"},{"key":"1843_CR37","doi-asserted-by":"crossref","unstructured":"Miwa H. Life style in persons with functional gastrointestinal disorders\u2014large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24:464\u201371, e217.","DOI":"10.1111\/j.1365-2982.2011.01872.x"},{"key":"1843_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2169\/internalmedicine.54.3056","volume":"54","author":"K Haruma","year":"2015","unstructured":"Haruma K, Kinoshita Y, Sakamoto S, et al. Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: primary care perspectives from the LEGEND study. Intern Med. 2015;54:695\u2013701.","journal-title":"Intern Med"},{"key":"1843_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3164\/jcbn.17-41","volume":"61","author":"S Hashimoto","year":"2017","unstructured":"Hashimoto S, Futagami S, Yamawaki H, et al. Epigastric pain syndrome accompanying pancreatic enzyme abnormalities was overlapped with early chronic pancreatitis using endosonography. J Clin Biochem Nutr. 2017;61:140\u20135.","journal-title":"J Clin Biochem Nutr"},{"key":"1843_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000492813","volume":"99","author":"H Yamawaki","year":"2019","unstructured":"Yamawaki H, Futagami S, Kaneko K, et al. Camostat mesilate, pancrelipase, and rabeprazole combination therapy improves epigastric pain in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities. Digestion. 2019;99:283\u201392.","journal-title":"Digestion"},{"key":"1843_CR41","doi-asserted-by":"publisher","first-page":"e0205165","DOI":"10.1371\/journal.pone.0205165","volume":"13","author":"M Wakabayashi","year":"2018","unstructured":"Wakabayashi M, Futagami S, Yamawaki H, et al. Comparison of clinical symptoms, gastric motility and fat intake in the early chronic pancreatitis patients with anti-acid therapy-resistant functional dyspepsia patients. PLoS ONE. 2018;13:e0205165.","journal-title":"PLoS ONE"},{"key":"1843_CR42","doi-asserted-by":"publisher","first-page":"e000144","DOI":"10.1136\/bmjgast-2017-000144","volume":"4","author":"M Igarashi","year":"2017","unstructured":"Igarashi M, Nakae H, Matsuoka T, et al. Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. BMJ Open Gastroenterol. 2017;4:e000144.","journal-title":"BMJ Open Gastroenterol"},{"key":"1843_CR43","doi-asserted-by":"publisher","first-page":"7490452","DOI":"10.1155\/2016\/7490452","volume":"2016","author":"A Takagi","year":"2016","unstructured":"Takagi A, Yanagi H, Ozawa H, et al. Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-associated dyspepsia: a multicenter randomized double-blind controlled trial. Gastroenterol Res Pract. 2016;2016:7490452.","journal-title":"Gastroenterol Res Pract"},{"key":"1843_CR44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/apt.13945","volume":"45","author":"VP Tan","year":"2017","unstructured":"Tan VP, Liu KS, Lam FY, et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2017;45:767\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MPG.0b013e318186008e","volume":"47","author":"MG Schappi","year":"2008","unstructured":"Schappi MG, Borrelli O, Knafelz D, et al. Mast cell-nerve interactions in children with functional dyspepsia. J Pediatr Gastroenterol Nutr. 2008;47:472\u201380.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1843_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/MPG.0b013e3181c2c28a","volume":"50","author":"NA Neilan","year":"2010","unstructured":"Neilan NA, Dowling PJ, Taylor DL, et al. Useful biomarkers in pediatric eosinophilic duodenitis and their existence: a case-control, single-blind, observational pilot study. J Pediatr Gastroenterol Nutr. 2010;50:377\u201384.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1843_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2982.2012.01876.x","volume":"24","author":"M Kusano","year":"2012","unstructured":"Kusano M, Hosaka H, Moki H, et al. Cascade stomach is associated with upper gastrointestinal symptoms: a population-based study. Neurogastroenterol Motil. 2012;24:451\u20135.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR48","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ajg.2017.154","volume":"112","author":"P Moayyedi","year":"2017","unstructured":"Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112:988\u20131013.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.gie.2015.04.003","volume":"82","author":"A Shaukat","year":"2015","unstructured":"Shaukat A, Wang A, Acosta RD, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc. 2015;82:227\u201332.","journal-title":"Gastrointest Endosc"},{"key":"1843_CR50","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMra1501505","volume":"373","author":"NJ Talley","year":"2015","unstructured":"Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853\u201363.","journal-title":"N Engl J Med"},{"key":"1843_CR51","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/00365529309098272","volume":"28","author":"E Dimenas","year":"1993","unstructured":"Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681\u20137.","journal-title":"Scand J Gastroenterol"},{"key":"1843_CR52","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2036.2006.02774.x","volume":"23","author":"SJ Veldhuyzen van Zanten","year":"2006","unstructured":"Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. Validation of a 7-point global overall symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Aliment Pharmacol Ther. 2006;23:521\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR53","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2169\/internalmedicine.50.5390","volume":"50","author":"E Kakuta","year":"2011","unstructured":"Kakuta E, Yamashita N, Katsube T, et al. Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med. 2011;50:1517\u201322.","journal-title":"Intern Med"},{"key":"1843_CR54","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1440-1746.2012.07121.x","volume":"27","author":"M Kusano","year":"2012","unstructured":"Kusano M, Hosaka H, Kawada A, et al. Development and evaluation of a modified frequency scale for the symptoms of gastroesophageal reflux disease to distinguish functional dyspepsia from non-erosive reflux disease. J Gastroenterol Hepatol. 2012;27:1187\u201391.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apt.12855","volume":"40","author":"J Tack","year":"2014","unstructured":"Tack J, Carbone F, Holvoet L, et al. The use of pictograms improves symptom evaluation by patients with functional dyspepsia. Aliment Pharmacol Ther. 2014;40:523\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"1843_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1440-1746.2011.06633.x","volume":"26","author":"H Miwa","year":"2011","unstructured":"Miwa H, Watari J, Fukui H, et al. Current understanding of pathogenesis of functional dyspepsia. J Gastroenterol Hepatol. 2011;26(Suppl 3):53\u201360.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR57","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/gutjnl-2018-316405","volume":"68","author":"P Vijayvargiya","year":"2019","unstructured":"Vijayvargiya P, Jameie-Oskooei S, Camilleri M, et al. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut. 2019;68:804\u201313.","journal-title":"Gut"},{"key":"1843_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5152\/tjg.2016.16281","volume":"27","author":"Y Kayar","year":"2016","unstructured":"Kayar Y, Danalioglu A, Kafee AA, et al. Gastric myoelectrical activity abnormalities of electrogastrography in patients with functional dyspepsia. Turk J Gastroenterol. 2016;27:415\u201320.","journal-title":"Turk J Gastroenterol"},{"key":"1843_CR59","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2982.2008.01092.x","volume":"20","author":"S Kindt","year":"2008","unstructured":"Kindt S, Coulie B, Wajs E, et al. Reproducibility and symptomatic predictors of a slow nutrient drinking test in health and in functional dyspepsia. Neurogastroenterol Motil. 2008;20:320\u20139.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR60","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1053\/j.gastro.2005.11.058","volume":"130","author":"EJ Irvine","year":"2006","unstructured":"Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538\u201351.","journal-title":"Gastroenterology"},{"key":"1843_CR61","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1572-0241.2007.01654.x","volume":"103","author":"N Vakil","year":"2008","unstructured":"Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008;103:1906\u201319.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR62","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;CD001960.","DOI":"10.1002\/14651858.CD001960.pub3"},{"key":"1843_CR63","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/j.1365-2036.2006.02845.x","volume":"23","author":"NJ Talley","year":"2006","unstructured":"Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther. 2006;23:923\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR64","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1365-2982.2008.01241.x","volume":"21","author":"P Enck","year":"2009","unstructured":"Enck P, Vinson B, Malfertheiner P, et al. The placebo response in functional dyspepsia\u2014reanalysis of trial data. Neurogastroenterol Motil. 2009;21:370\u20137.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR65","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1053\/j.gastro.2016.02.027","volume":"150","author":"L Van Oudenhove","year":"2016","unstructured":"Van Oudenhove L, Crowell MD, Drossman DA, et al. Biopsychosocial aspects of functional gastrointestinal disorders. Gastroenterology. 2016;150:1355\u201367.","journal-title":"Gastroenterology"},{"key":"1843_CR66","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1111\/j.1572-0241.2008.02041.x","volume":"103","author":"AN Pilichiewicz","year":"2008","unstructured":"Pilichiewicz AN, Feltrin KL, Horowitz M, et al. Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol. 2008;103:2613\u201323.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR67","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.bpg.2017.09.006","volume":"31","author":"B Ohlsson","year":"2017","unstructured":"Ohlsson B. The role of smoking and alcohol behaviour in management of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol. 2017;31:545\u201352.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1843_CR68","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/apt.12444","volume":"38","author":"R Iwakiri","year":"2013","unstructured":"Iwakiri R, Tominaga K, Furuta K, et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38:729\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR69","first-page":"CD011194","volume":"11","author":"MI Pinto-Sanchez","year":"2017","unstructured":"Pinto-Sanchez MI, Yuan Y, Hassan A, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11:CD011194.","journal-title":"Cochrane Database Syst Rev"},{"key":"1843_CR70","doi-asserted-by":"publisher","first-page":"618-e173","DOI":"10.1111\/j.1365-2982.2009.01449.x","volume":"22","author":"K Matsueda","year":"2010","unstructured":"Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia\u2014100\u00a0mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22:618-e173.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR71","first-page":"CD009431","volume":"10","author":"R Pittayanon","year":"2018","unstructured":"Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev. 2018;10:CD009431.","journal-title":"Cochrane Database Syst Rev"},{"key":"1843_CR72","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00535-013-0788-z","volume":"48","author":"K Tominaga","year":"2013","unstructured":"Tominaga K, Arakawa T. Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application. J Gastroenterol. 2013;48:452\u201362.","journal-title":"J Gastroenterol"},{"key":"1843_CR73","doi-asserted-by":"publisher","first-page":"e13319","DOI":"10.1111\/nmo.13319","volume":"30","author":"K Tominaga","year":"2018","unstructured":"Tominaga K, Sakata Y, Kusunoki H, et al. Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: a randomized clinical trial (the DREAM study). Neurogastroenterol Motil. 2018;30:e13319.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR74","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.3748\/wjg.v18.i48.7371","volume":"18","author":"X Huang","year":"2012","unstructured":"Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18:7371\u20137.","journal-title":"World J Gastroenterol"},{"key":"1843_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1440-1746.2011.06949.x","volume":"27","author":"M Hongo","year":"2012","unstructured":"Hongo M, Harasawa S, Mine T, et al. Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol. 2012;27:62\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR76","doi-asserted-by":"publisher","first-page":"e0157798","DOI":"10.1371\/journal.pone.0157798","volume":"11","author":"Y Lu","year":"2016","unstructured":"Lu Y, Chen M, Huang Z, et al. Antidepressants in the treatment of functional dyspepsia: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0157798.","journal-title":"PLoS ONE"},{"key":"1843_CR77","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/gutjnl-2015-310721","volume":"66","author":"AC Ford","year":"2017","unstructured":"Ford AC, Luthra P, Tack J, et al. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:411\u201320.","journal-title":"Gut"},{"key":"1843_CR78","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1038\/ajg.2009.427","volume":"104","author":"H Miwa","year":"2009","unstructured":"Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009;104:2779\u201387.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR79","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1046\/j.1365-2036.2001.01074.x","volume":"15","author":"NJ Talley","year":"2001","unstructured":"Talley NJ, Riff DS, Schwartz H, et al. Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15:1603\u201311.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR80","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1111\/j.1440-1746.2006.04446.x","volume":"21","author":"H Miwa","year":"2006","unstructured":"Miwa H, Osada T, Nagahara A, et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006;21:1826\u201331.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR81","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/0022-3999(94)90026-4","volume":"38","author":"TT Haug","year":"1994","unstructured":"Haug TT, Wilhelmsen I, Svebak S, et al. Psychotherapy in functional dyspepsia. J Psychosom Res. 1994;38:735\u201344.","journal-title":"J Psychosom Res"},{"key":"1843_CR82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpsychores.2015.03.003","volume":"78","author":"M Orive","year":"2015","unstructured":"Orive M, Barrio I, Orive VM, et al. A randomized controlled trial of a 10\u00a0week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia. J Psychosom Res. 2015;78:563\u20138.","journal-title":"J Psychosom Res"},{"key":"1843_CR83","doi-asserted-by":"crossref","unstructured":"Lan L, Zeng F, Liu GJ, et al. Acupuncture for functional dyspepsia. Cochrane Database Syst Rev. 2014;CD008487.","DOI":"10.1002\/14651858.CD008487.pub2"},{"key":"1843_CR84","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M19-2880","volume":"172","author":"JW Yang","year":"2020","unstructured":"Yang JW, Wang LQ, Zou X, et al. Effect of acupuncture for postprandial distress syndrome: a randomized clinical trial. Ann Intern Med. 2020;172:777\u201385.","journal-title":"Ann Intern Med"},{"key":"1843_CR85","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","volume":"32","author":"AC Ford","year":"2010","unstructured":"Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32:144\u201358.","journal-title":"Aliment Pharmacol Ther"},{"key":"1843_CR86","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/003655299750026010","volume":"34","author":"V Meineche-Schmidt","year":"1999","unstructured":"Meineche-Schmidt V, Talley NJ, Pap A, et al. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study. Scand J Gastroenterol. 1999;34:566\u201374.","journal-title":"Scand J Gastroenterol"},{"key":"1843_CR87","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15403\/jgld.2014.1121.264.ski","volume":"26","author":"S Shinozaki","year":"2017","unstructured":"Shinozaki S, Osawa H, Sakamoto H, et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26:345\u201350.","journal-title":"J Gastrointestin Liver Dis"},{"key":"1843_CR88","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/ajg.2010.40","volume":"105","author":"JY Chang","year":"2010","unstructured":"Chang JY, Locke GR 3rd, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105:822\u201332.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR89","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/ajg.2012.69","volume":"107","author":"AC Ford","year":"2012","unstructured":"Ford AC, Forman D, Bailey AG, et al. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol. 2012;107:912\u201321.","journal-title":"Am J Gastroenterol"},{"key":"1843_CR90","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1136\/gut.2004.053355","volume":"54","author":"J Tack","year":"2005","unstructured":"Tack J, Caenepeel P, Arts J, et al. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut. 2005;54:1370\u20136.","journal-title":"Gut"},{"key":"1843_CR91","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/gut.2008.175810","volume":"58","author":"E Savarino","year":"2009","unstructured":"Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut. 2009;58:1185\u201391.","journal-title":"Gut"},{"key":"1843_CR92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cgh.2017.07.041","volume":"16","author":"LH Eusebi","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Bazzoli F, et al. Prevalence of dyspepsia in individuals with gastroesophageal reflux-type symptoms in the community: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:39-48 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1843_CR93","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1053\/j.gastro.2016.02.014","volume":"150","author":"OS Palsson","year":"2016","unstructured":"Palsson OS, Whitehead WE, van Tilburg MA, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 2016;150:1481\u201391.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"1843_CR94","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1111\/j.1440-1746.2010.06244.x","volume":"25","author":"S Nakajima","year":"2010","unstructured":"Nakajima S, Takahashi K, Sato J, et al. Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol. 2010;25(Suppl 1):S138\u201343.","journal-title":"J Gastroenterol Hepatol"},{"key":"1843_CR95","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/gutjnl-2011-301454","volume":"61","author":"K Matsueda","year":"2012","unstructured":"Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61:821\u20138.","journal-title":"Gut"},{"key":"1843_CR96","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/2050640613510904","volume":"1","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Kusunoki H, Kamiya T, et al. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): a multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United Eur Gastroenterol J. 2013;1:445\u201352.","journal-title":"United Eur Gastroenterol J"},{"key":"1843_CR97","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/nmo.12348","volume":"26","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Matsuzaki J, Fukushima Y, et al. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia\u2014a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil. 2014;26:950\u201361.","journal-title":"Neurogastroenterol Motil"},{"key":"1843_CR98","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000479000","volume":"96","author":"T Ohtsu","year":"2017","unstructured":"Ohtsu T, Takagi A, Uemura N, et al. The ameliorating effect of Lactobacillus gasseri OLL2716 on functional dyspepsia in Helicobacter pylori-uninfected individuals: a randomized controlled study. Digestion. 2017;96:92\u2013102.","journal-title":"Digestion"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-021-01843-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:38:07Z","timestamp":1700084287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-021-01843-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s00535-021-01843-7","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are as follows: (1) those from which the authors, the spouse, partner or immediate relatives of the authors have received individually any income, honoraria or any other type of remuneration; Astellas Pharma, AstraZeneca, Otsuka Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Kobayashi Pharmaceutical, Mochida Pharmaceutical, Tsumura & CO., Fujifilm Medical, EA Pharma, Zeria Pharmaceutical, Sumitomo Dainippon Pharma, Mylan EPD, LIXIL, and (2) those from which the authors have received research grant: Taiho Pharmaceutical, Tsumura & CO, Bristol-Myers Squibb, Tosoh, and (3) those from which the authors have received scholarship; Astellas Pharma, AbbVie, EA Pharma, Eisai, MSD, Ono Pharmaceutical, Covidien Japan, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Novartis Pharma, Bayer Yakuhin, Asahi Kasei Pharma, Nippon Kayaku, Mochida Pharmaceutical, Zeria Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Dainippon Pharma, Saisei Mirai Clinics, Welfare Kyushu Hospital, Kracie Pharmaceutical, Tsukasa Health Care Hospital, Tsumura & CO, Mitsubishi Tanabe Pharma, Fujifilm Medical, and (4) those from which the authors have received individually endowed chair; Kinshukai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}